User profiles for John H. Beigel
 | John H. Beigel, MDNational Institute of Allergy and Infectious Diseases Verified email at niaid.nih.gov Cited by 27032 |
[HTML][HTML] Remdesivir for the treatment of Covid-19
Background Although several therapeutic agents have been evaluated for the treatment of
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
…, ES Yang, mRNA-1273 Study Group §, JH Beigel… - Science, 2021 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …
[HTML][HTML] An mRNA vaccine against SARS-CoV-2—preliminary report
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged
in late 2019 and spread globally, prompting an international effort to accelerate development …
in late 2019 and spread globally, prompting an international effort to accelerate development …
Remdesivir for the treatment of Covid-19—preliminary report
… Beigel at the National Institute of Allergy and Infectious Diseases, National Institutes of Health,
… The authors’ full names and academic degrees are as follows: John H. Beigel, MD, Kay M. …
… The authors’ full names and academic degrees are as follows: John H. Beigel, MD, Kay M. …
[HTML][HTML] Baricitinib plus remdesivir for hospitalized adults with Covid-19
Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated
inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, …
inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, …
[HTML][HTML] Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19
…, W Buchanan, CJ Luke, JH Beigel… - … England Journal of …, 2021 - Mass Medical Soc
Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received
both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn …
both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn …
[HTML][HTML] Homologous and heterologous Covid-19 booster vaccinations
…, DS Stephens, PC Roberts, JH Beigel - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …
have received emergency use authorization in the United States are highly effective, …
[HTML][HTML] Durability of responses after SARS-CoV-2 mRNA-1273 vaccination
Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two
100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein …
100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein …
[HTML][HTML] SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination
…, NJ Sullivan, PC Roberts, JH Beigel… - … England Journal of …, 2022 - Mass Medical Soc
Omicron Neutralization and mRNA-1273 Boosters Neutralization of the omicron variant was
assessed in serum samples obtained from persons who had received an mRNA-1273 …
assessed in serum samples obtained from persons who had received an mRNA-1273 …
[HTML][HTML] Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
Background Testing of vaccine candidates to prevent infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …
